An integrated analysis of germline and somatic, genetic and epigenetic alterations at 9p21.3 in glioblastoma

Cancer

Volumn 118, Issue 1, 2012, Pages 232-240

  Feng, Junjie ^a   Kim, Seong Tae ^a   Liu, Wennuan ^a   Kim, Jin Woo ^a   Zhang, Zheng ^a   Zhu, Yi ^a   Berens, Michael ^b   Sun, Jielin ^a   Xu, Jianfeng ^a,b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

CDKN2A; CDKN2B; copy number alterations; DNA methylation; glioblastoma; microRNAs

Indexed keywords

MESSENGER RNA; MICRORNA; MICRORNA 125B; MICRORNA 126; MICRORNA 517A; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN TISSUE; CDKN2A GENE; CDKN2B GENE; CHILD; CHROMOSOME 9P; CHROMOSOME 9P21.3; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA METHYLATION; GENE EXPRESSION; GENETIC ANALYSIS; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CHILD; CHROMOSOMES, HUMAN, PAIR 9; DNA COPY NUMBER VARIATIONS; DNA METHYLATION; FEMALE; GENES, P16; GERM CELLS; GLIOBLASTOMA; HUMANS; MALE; MICRORNAS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS;

EID: 83855164166     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26250     Document Type: Article

References (20)

1. Bondy ML, Scheurer ME, Malmer B, et al. Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer. 2008; 113 (7 suppl): 1953-1968.
2. Canepa ET, Scassa ME, Ceruti JM, et al. INK4 proteins, a family of mammalian CDK inhibitors with novel biological functions. IUBMB Life. 2007; 59: 419-426. (Pubitemid 47123998)
3. Matheu A, Maraver A, Serrano M,. The Arf/p53 pathway in cancer and aging. Cancer Res. 2008; 68: 6031-6034.
4. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994; 264: 436-440.
5. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA,. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 1994; 368: 753-756. (Pubitemid 24153417)
6. Schmidt EE, Ichimura K, Reifenberger G, Collins VP,. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res. 1994; 54: 6321-6324.
7. Bahuau M, Vidaud D, Jenkins RB, et al. Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors. Cancer Res. 1998; 58: 2298-2303. (Pubitemid 28252682)
8. Shete S, Hosking FJ, Robertson LB, et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet. 2009; 41: 899-904.
9. Wrensch M, Jenkins RB, Chang JS, et al. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet. 2009; 41: 905-908.
10. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455: 1061-1068.
11. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321: 1807-1812.
12. Wager M, Menei P, Guilhot J, et al. Prognostic molecular markers with no impact on decision-making: the paradox of gliomas based on a prospective study. Br J Cancer. 2008; 98: 1830-1838. (Pubitemid 351748843)
13. Wemmert S, Bettscheider M, Alt S, et al. p 15 promoter methylation-a novel prognostic marker in glioblastoma patients. Int J Oncol. 2009; 34: 1743-1748.
14. Lal A, Kim HH, Abdelmohsen K, et al. p16(INK4a) translation suppressed by miR-24. PLoS One. 2008; 3: e1864.
15. Pogue AI, Cui JG, Li YY, Zhao Y, Culicchia F, Lukiw WJ,. Micro RNA-125b (miRNA-125b) function in astrogliosis and glial cell proliferation. Neurosci Lett. 2010; 476: 18-22.
16. Ciafre SA, Galardi S, Mangiola A, et al. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun. 2005; 334: 1351-1358. (Pubitemid 41074723)
17. Hannon GJ, Beach D,. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature. 1994; 371: 257-261.
18. Feng XH, Liang YY, Liang M, Zhai W, Lin X,. Direct interaction of c-Myc with Smad2 and Smad3 to inhibit TGF-beta-mediated induction of the CDK inhibitor p15(Ink4B). Mol Cell. 2002; 9: 133-143. (Pubitemid 34127777)
19. Brat DJ, Seiferheld WF, Perry A, et al. Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group trials. Neuro Oncol. 2004; 6: 96-103. (Pubitemid 38455755)
20. Krimpenfort P, Ijpenberg A, Song JY, et al. p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a. Nature. 2007; 448: 943-946. (Pubitemid 47312779)